Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Laboratory tests to support the clinical diagnosis of anaphylaxis

INTRODUCTION

Anaphylaxis is a serious systemic allergic reaction that is rapid in onset and may cause death [1]. The diagnosis of anaphylaxis during the acute event is based on the clinical presentation and a history of a recent exposure to an offending agent [1]. Currently, there are no laboratory tests available in an emergency department or clinic setting to confirm a diagnosis of anaphylaxis in real time. (See "Anaphylaxis: Rapid recognition and treatment".)

Serum, plasma, and possibly urine obtained during or shortly after the acute event, can, however, help to support the clinical diagnosis of anaphylaxis. These tests can also help identify anaphylaxis in the presence of other disorders that have overlapping clinical presentations, such as severe asthma or myocardial infarction. In addition, these tests may provide evidence for anaphylaxis as a cause of death.

This topic reviews the laboratory tests that can be used to support the clinical diagnosis of anaphylaxis in both adults and children. These tests are different from those that identify sensitization to the inciting allergen, namely measurements of allergen-specific immunoglobulin E (IgE), which are reviewed elsewhere. (See "Overview of skin testing for allergic disease" and "Overview of in vitro allergy tests" and "Anaphylaxis: Confirming the diagnosis and determining the trigger(s)", section on 'Testing for allergen trigger(s)'.)

OVERVIEW

The principal effector cells of systemic anaphylaxis are mast cells and basophils. The various preformed and newly-generated mediators secreted by these cells cause many of the signs and symptoms of systemic anaphylaxis. The pathophysiology of anaphylaxis is reviewed in detail separately. (See "Pathophysiology of anaphylaxis".)

Two of the most abundant and best-characterized preformed granule mediators released by these cells during anaphylaxis are tryptase and histamine. Elevations in tryptase and histamine can sometimes be detected in blood samples obtained shortly after the onset of symptoms. Also, elevated levels of histamine, histamine metabolites (N-methylhistamine and N-methylimidazole acetic acid) and the prostaglandin (PG) D2 metabolite, 11-beta-PGF2-alpha (11β-PGF), can be measured in urine after an anaphylactic event.

                              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Sep 13, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.
  2. Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.
  3. Schwartz LB, Yunginger JW, Miller J, et al. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989; 83:1551.
  4. van der Linden PW, Hack CE, Poortman J, et al. Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol 1992; 90:110.
  5. van der Linden PW, Struyvenberg A, Kraaijenhagen RJ, et al. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med 1993; 118:161.
  6. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072.
  7. Halmerbauer G, Hauk P, Forster J, et al. In vivo histamine release during the first minutes after deliberate sting challenges correlates with the severity of allergic symptoms. Pediatr Allergy Immunol 1999; 10:53.
  8. Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987; 138:2184.
  9. Jogie-Brahim S, Min HK, Fukuoka Y, et al. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol 2004; 113:1086.
  10. Schwartz LB, Irani AM, Roller K, et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987; 138:2611.
  11. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.
  12. Schwartz LB, Min HK, Ren S, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol 2003; 170:5667.
  13. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007; 217:141.
  14. Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J Biol Chem 1986; 261:7372.
  15. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J Immunol 1992; 148:2475.
  16. Le QT, Min HK, Xia HZ, et al. Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C. J Immunol 2011; 186:7136.
  17. Pereira PJ, Bergner A, Macedo-Ribeiro S, et al. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 1998; 392:306.
  18. ImmunoCAP Tryptase, Phadia AB, Uppsala, Sweden. www.phadia.com (Accessed on May 24, 2010).
  19. The author's laboratory can provide additional information to clinicians regarding sample preparation, cost, shipping, and interpretation of results. The laboratory can be contacted at (804) 828-9685.
  20. Edston E, van Hage-Hamsten M. beta-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci Int 1998; 93:135.
  21. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190.
  22. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215.
  23. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.
  24. Ruëff F, Przybilla B, Biló MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105.
  25. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.
  26. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.
  27. Yunginger JW, Nelson DR, Squillace DL, et al. Laboratory investigation of deaths due to anaphylaxis. J Forensic Sci 1991; 36:857.
  28. Shen Y, Li L, Grant J, et al. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009; 186:1.
  29. Mayer DE, Krauskopf A, Hemmer W, et al. Usefulness of post mortem determination of serum tryptase, histamine and diamine oxidase in the diagnosis of fatal anaphylaxis. Forensic Sci Int 2011; 212:96.
  30. Randall B, Butts J, Halsey JF. Elevated postmortem tryptase in the absence of anaphylaxis. J Forensic Sci 1995; 40:208.
  31. Bosso JV, Schwartz LB, Stevenson DD. Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol 1991; 88:830.
  32. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94:1046.
  33. Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26:807.
  34. Silvers WS, Essember LJ, Williams PB, et al. Anaphylaxis due to Diclofenac Sodium (Voltaren): Evidence of mast cell mediator release. Immunol Allergy Pract 1991; 13:193.
  35. The FO, Bennink RJ, Ankum WM, et al. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut 2008; 57:33.
  36. Platt MS, Yunginger JW, Sekula-Perlman A, et al. Involvement of mast cells in sudden infant death syndrome. J Allergy Clin Immunol 1994; 94:250.
  37. Schwartz HJ, Yunginger JW, Schwartz LB. Is unrecognized anaphylaxis a cause of sudden unexpected death? Clin Exp Allergy 1995; 25:866.
  38. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114:3.
  39. http://www.accessdata.fda.gov/cdrh_docs/reviews/K103039.pdf (Accessed on September 13, 2012).
  40. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001; 98:2200.
  41. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002; 43:1097.
  42. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660.
  43. Brezin AL, Brezin JH, Raible DG, et al. Elevated stem cell factor and a-protryptase levels in uremia. J Allergy Clin Immunol 1999; 103:S233 (Abstract).
  44. Dugas-Breit S, Schöpf P, Dugas M, et al. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005; 3:343.
  45. Cooper PJ, Schwartz LB, Irani AM, et al. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin. J Infect Dis 2002; 186:1307.
  46. Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681.
  47. Kanthawatana S, Carias K, Arnaout R, et al. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol 1999; 103:1092.
  48. Sargur R, Cowley D, Murng S, et al. Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay. Clin Exp Immunol 2011; 163:339.
  49. van Toorenenbergen AW, van Daele PL, Boonstra JG. False-elevated serum tryptase assay result caused by heterophilic antibodies. J Allergy Clin Immunol 2005; 116:1159.
  50. van Toorenenbergen AW, Hooijkaas H, Heerenbrink GK, Dufour-van den Goorbergh DM. Heterophilic antibody interference in a tryptase immunoassay. Clin Biochem 2008; 41:331.
  51. Laroche D, Vergnaud MC, Dubois F, et al. Plasma histamine and tryptase during anaphylactoid reactions. Agents Actions 1992; 36:C201.
  52. Stephan V, Zimmermann A, Kühr J, Urbanek R. Determination of N-methylhistamine in urine as an indicator of histamine release in immediate allergic reactions. J Allergy Clin Immunol 1990; 86:862.
  53. Takeda J, Ueda E, Takahashi J, Fukushima K. Plasma N-methylhistamine concentration as an indicator of histamine release by intravenous d-tubocurarine in humans: preliminary study in five patients by radioimmunoassay kits. Anesth Analg 1995; 80:1015.
  54. Schulze S, Niggemann B, Savaser AN, Wahn U. Diurnal variation of urinary histamine and 1-methylhistamine excretion in healthy children. Allergy 1992; 47:644.
  55. Oosting E, Keyzer JJ, Wolthers BG, Scholtis RJ. Age dependent normal values of histamine and histamine metabolites in human urine. Agents Actions 1988; 23:307.
  56. Laroche D, Dubois F, Lefrançois C, et al. [Early biological markers of anaphylactoid reactions occurring during anesthesia]. Ann Fr Anesth Reanim 1992; 11:613.
  57. Keyzer JJ, van Saene HK, van den Berg GA, Wolthers BG. Influence of decontamination of the digestive tract on the urinary excretion of histamine and some of its metabolites. Agents Actions 1984; 15:238.
  58. Keyzer JJ, Breukelman H, Wolthers BG, et al. Urinary excretion of histamine and some of its metabolites in man: influence of the diet. Agents Actions 1984; 15:189.
  59. Oosting E, Keyzer JJ, Wolthers BG. Correlation between urinary levels of histamine metabolites in 24-hour urine and morning urine samples of man: influence of histamine-rich food. Agents Actions 1989; 27:205.
  60. Morrow JD, Margolies GR, Rowland J, Roberts LJ 2nd. Evidence that histamine is the causative toxin of scombroid-fish poisoning. N Engl J Med 1991; 324:716.
  61. Hershko AY, Dranitzki Z, Ulmanski R, et al. Constitutive hyperhistaminaemia: a possible mechanism for recurrent anaphylaxis. Scand J Clin Lab Invest 2001; 61:449.
  62. Roberts LJ 2nd, Sweetman BJ, Lewis RA, et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980; 303:1400.
  63. Awad JA, Morrow JD, Roberts LJ 2nd. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol 1994; 93:817.
  64. Morrow JD, Guzzo C, Lazarus G, et al. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995; 104:937.
  65. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008; 147:338.
  66. Assays of urinary prostaglandins are available throught Mayo Medical Laboratories. www.mayomedicallaboratories.com (Accessed on June 14, 2010).
  67. Schwartz LB. Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol 2006; 315:53.
  68. Nishio H, Takai S, Miyazaki M, et al. Usefulness of serum mast cell-specific chymase levels for postmortem diagnosis of anaphylaxis. Int J Legal Med 2005; 119:331.
  69. Zhou X, Buckley MG, Lau LC, et al. Mast Cell Carboxypeptidase as a New Clinical Marker for Anaphylaxis. J Allergy Clin Immunol 2006; 117:S85.
  70. Brown TA, Whitworth HS, Zhou XY, et al. Mast cell carboxypeptidase as a confirmatory and predictive marker in allergic reactions to drugs. J Allergy Clin Immunol 2011; 127:Abstract 143.
  71. Ono E, Taniguchi M, Mita H, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2009; 39:72.